| Helder H Chin, MD | |
|
4450 Fashion Square Blvd, Saginaw, MI 48603-1251 | |
| (989) 792-4090 | |
| (989) 792-4094 |
| Full Name | Helder H Chin |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 16 Years |
| Location | 4450 Fashion Square Blvd, Saginaw, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740571736 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 4301101775 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| El Camino Hospital | Mountain view, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| El Camino Anesthesia | 7517360639 | 55 |
News Archive
With a team of more than thirty public and private organisations and a budget over 200 million euro, ERA4TB aims to radically transform the way in which new therapies are developed for the treatment of tuberculosis.
Today, the FDA issued a draft guidance encouraging industry to include patients with incurable cancers (when there is no potential for cure or for prolonged/near normal survival) in cancer clinical trials, regardless of whether they have received existing alternative treatment options.
In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of the two drugs showed a statistically significant elevated risk of heart attack relative to people who did not use the drugs.
A team of researchers from Imperial College London's Division of Molecular Biosciences has received a grant of over US $4 million to support a research facility for understanding how sugars are involved in cell to cell communication.
Recent research indicates that only half of the cancer drugs approved by the European Medicines Agency (EMA) showed benefit in patients.
› Verified 3 days ago
| Entity Name | Fidere Anesthesia Consultants Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790855161 PECOS PAC ID: 6507769593 Enrollment ID: O20040426001885 |
News Archive
With a team of more than thirty public and private organisations and a budget over 200 million euro, ERA4TB aims to radically transform the way in which new therapies are developed for the treatment of tuberculosis.
Today, the FDA issued a draft guidance encouraging industry to include patients with incurable cancers (when there is no potential for cure or for prolonged/near normal survival) in cancer clinical trials, regardless of whether they have received existing alternative treatment options.
In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of the two drugs showed a statistically significant elevated risk of heart attack relative to people who did not use the drugs.
A team of researchers from Imperial College London's Division of Molecular Biosciences has received a grant of over US $4 million to support a research facility for understanding how sugars are involved in cell to cell communication.
Recent research indicates that only half of the cancer drugs approved by the European Medicines Agency (EMA) showed benefit in patients.
› Verified 3 days ago
| Entity Name | El Camino Anesthesia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356910053 PECOS PAC ID: 7517360639 Enrollment ID: O20210727004102 |
News Archive
With a team of more than thirty public and private organisations and a budget over 200 million euro, ERA4TB aims to radically transform the way in which new therapies are developed for the treatment of tuberculosis.
Today, the FDA issued a draft guidance encouraging industry to include patients with incurable cancers (when there is no potential for cure or for prolonged/near normal survival) in cancer clinical trials, regardless of whether they have received existing alternative treatment options.
In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of the two drugs showed a statistically significant elevated risk of heart attack relative to people who did not use the drugs.
A team of researchers from Imperial College London's Division of Molecular Biosciences has received a grant of over US $4 million to support a research facility for understanding how sugars are involved in cell to cell communication.
Recent research indicates that only half of the cancer drugs approved by the European Medicines Agency (EMA) showed benefit in patients.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Helder H Chin, MD 4450 Fashion Square Blvd, Saginaw, MI 48603-1251 Ph: (989) 792-4090 | Helder H Chin, MD 4450 Fashion Square Blvd, Saginaw, MI 48603-1251 Ph: (989) 792-4090 |
News Archive
With a team of more than thirty public and private organisations and a budget over 200 million euro, ERA4TB aims to radically transform the way in which new therapies are developed for the treatment of tuberculosis.
Today, the FDA issued a draft guidance encouraging industry to include patients with incurable cancers (when there is no potential for cure or for prolonged/near normal survival) in cancer clinical trials, regardless of whether they have received existing alternative treatment options.
In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of the two drugs showed a statistically significant elevated risk of heart attack relative to people who did not use the drugs.
A team of researchers from Imperial College London's Division of Molecular Biosciences has received a grant of over US $4 million to support a research facility for understanding how sugars are involved in cell to cell communication.
Recent research indicates that only half of the cancer drugs approved by the European Medicines Agency (EMA) showed benefit in patients.
› Verified 3 days ago
Dr. Scott Marshall Placeway, D.O. Anesthesiology Medicare: Medicare Enrolled Practice Location: 1447 N Harrison St, Saginaw, MI 48602 Phone: 989-583-4511 | |
Dr. Jeffrey Scott Smith, DO Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 700 Cooper Ave, Saginaw, MI 48602 Phone: 989-583-6200 | |
Vasil Mamaladze, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1447 N Harrison St, Saginaw, MI 48602 Phone: 989-583-0000 | |
Dr. Lakshmana R Madala, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1119 S Washington Ave, Saginaw, MI 48601 Phone: 989-752-1900 Fax: 989-752-1901 | |
Dr. Perlita P. Ilem, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1447 N Harrison St, Saginaw, MI 48602 Phone: 989-583-4511 | |
Dr. Syed Khursheed Alam, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 700 Cooper Ave, Saginaw, MI 48602 Phone: 989-583-6200 Fax: 989-583-7356 | |
Ramesh Penumetsa Raju,, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 590 Canterbury Dr, Saginaw, MI 48638 Phone: 989-776-8033 |